OMNIAB, INC. (OABI) Quick Ratio
- Quick ratio · latest quarter: Value 4.53×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 4.53× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $62.32M ÷ $13.76M ≈ 4.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 62.32M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 13.76M USD | Liabilities, Current |
| Cash and equivalents | 24.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 27.66M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 10.33M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.01M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $62.32M | $13.76M | $24.34M | $27.66M | $10.33M | $1.01M | 4.53× |
| 2026-03-31 | $61.71M | $13.57M | $29.05M | $20.03M | $12.64M | $920.00K | 4.55× |
| 2025-12-31 | $61.41M | $16.25M | $25.52M | $28.50M | $7.39M | $823.00K | 3.78× |
| 2025-09-30 | $62.59M | $13.28M | $28.54M | $30.96M | $3.10M | $443.00K | 4.71× |
| 2025-06-30 | $44.32M | $12.64M | $18.28M | $23.33M | $2.71M | $316.00K | 3.51× |
| 2025-03-31 | $50.07M | $11.41M | $10.89M | $32.70M | $6.48M | (m) | 4.39× |
| 2024-12-31 | $64.71M | $15.09M | $27.60M | $31.84M | $5.27M | (m) | 4.29× |
| 2024-09-30 | $62.88M | $14.40M | $27.24M | $32.15M | $3.50M | (m) | 4.37× |
| 2024-06-30 | $64.10M | $14.15M | $20.79M | $36.43M | $6.88M | (m) | 4.53× |
| 2024-03-31 | $73.05M | $17.52M | $19.06M | $49.95M | $4.04M | (m) | 4.17× |
| 2023-12-31 | $90.83M | $23.12M | $16.36M | $70.63M | $3.84M | (m) | 3.93× |
| 2023-09-30 | $102.77M | $25.06M | $21.25M | $75.38M | $6.14M | (m) | 4.10× |
| 2023-06-30 | $111.76M | $24.24M | $20.99M | $82.16M | $8.61M | (m) | 4.61× |
| 2023-03-31 | $115.42M | $21.68M | $22.91M | $90.70M | $1.82M | (m) | 5.32× |
| 2022-12-31 | $118.56M | $26.02M | $33.39M | $54.88M | $30.29M | (m) | 4.56× |
| 2022-11-01 | (m) | $12.26M | $98.08M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $10.27M | $19.85K | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $6.98M | $159.19K | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.46M | $434.63K | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $438.21K | $189.97K | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $95.97K | $362.20K | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $36.15K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |